Clinical Trial Update: Real-life Efficacy and Toxicity of Brentuximab-Vedotin Associated With Bendamustine in Patients With Relapsed or Refractory Hodgkin Lymphoma (HL-R2-B2)

View source ↗

Summary

This clinical trial update reports real-world efficacy and toxicity data for the combination of Brentuximab vedotin with Bendamustine in patients with relapsed …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• Bendamustine (Bendamustine)
• Brentuximab vedotin (Brentuximab vedotin)

Snippet

Sponsor: University Hospital, Bordeaux | Conditions: Relapsed or Refractory Hodgkin Lymphoma | Status: COMPLETED